Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Monograph Bill Has Energy And Commerce Date, CDER Director's Hope

Executive Summary

US House is catching up with Senate on OTC monograph legislation, with a committee markup expected in the next few days.

Related Content

Rulemaking For OTC Switch Process Changes Pushed To 2019
Senate OTC Monograph Reform Bill Clears HELP For Floor Vote
Opioid Legislation Would Require US FDA Guidance On Non-Opioid Pain Medication Development
Shorter Exclusivity In House OTC Monograph Bill Could Gain Industry Acceptance To Speed Passage
OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
OTC Monograph User Fees Totaling $22m To $34m Floated In Senate Discussion Draft
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts